Navigation Links
GranuFlo Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Conference in Federal GranuFlo Recall Litigation
Date:9/20/2013

New York, New York (PRWEB) September 20, 2013

Hundreds of GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) filed on behalf of patients who allegedly suffered serious heart problems related to the 2012 recall of GranuFlo and NaturaLyte dialysis concentrates continue to move forward in the federal multidistrict litigation in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to court documents, the Court will convene a Status Conference on September 27, 2013. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“Our Firm hears from dialysis patients affected by the GranuFlo recall on a regular basis. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the administration of GranuFlo and NaturaLyte during dialysis treatments.

GranuFlo Recall Lawsuits
Both GranuFlo and NaturaLyte are marketed by Fresenius Medical Care and used during dialysis to remove toxins from the blood. According to The New York Times, prior to the GranuFlo recall, both were widely used at Fresenius’ own dialysis clinics, and were also used to treat an estimated 125,000 patients at clinics outside of the Fresenius network. *

In March of 2012 Fresenius issued an Urgent Product Notification to dialysis clinics across the country after GranuFlo and NaturaLyte were linked to a rapid and unsafe elevation of bicarbonate, which creates a substantially increased risk of cardiopulmonary arrest and death. Several months later, the U.S. Food & Drug Administration (FDA) deemed the notification a Class I GranuFlo recall, a designation that is only granted when a medical product poses a significant risk of serious injury or death. According to the Times, the FDA later launched an investigation of Fresenius Medical Care shortly after learning that the company had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. The agency is trying to determine if Fresenius’ delay in notifying dialysis clinics outside of its network violated any federal regulations.*

Court records indicate that more than 300 GranuFlo lawsuits have been filed in courts throughout the U.S., all of which allege that Fresenius Medical Care failed to provide adequate warnings regarding the use of the products, and assert that the company continued to aggressively market GranuFlo and NaturaLyte even after the company became aware of their dangers. In addition to the federal litigation, GranuFlo lawsuits have also been consolidated at the state level in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)

Dialysis patients who suffered sudden and life-threatening heart problems, including cardiac arrest, heart attacks, stroke, and sudden cardiac death, within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to compensation for their injury-related damages. Click Here to learn how to contact a GranuFlo lawyer at Bernstein Liebhard LLP. For additional information, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.thegranuflolawsuit.com/

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11146129.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. GranuFlo Lawsuits Mount, as Bernstein Liebhard LLP Notes New Consolidated Litigation for GranuFlo Recall Claims Filed in Massachusetts State Court
2. GranuFlo Lawsuit News: Bernstein Liebhard LLP Comments on Fresenius FDA Warning Letter, as GranuFlo Recall Claims Mount
3. GranuFlo Lawsuits News: Calif. Lawsuit Alleges Drug Maker Hid Serious Health Risks, Rottenstein Law Group LLP Reports
4. 201 Actions Pending in the Granuflo Multidistrict Litigation: Now, AttorneyOne Can Provide Advice
5. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Conference in Federal GranuFlo Recall Litigation
6. NaturaLyte and GranuFlo Lawsuits Are Heating Up
7. New Fresenius NaturaLyte, GranuFlo Dialysis Heart Attack Lawsuit Allegations Update: Resource4thePeople Reports Important Hearing Is Scheduled in Fresenius Multidistrict Litigation
8. Rottenstein Law Group LLP Announces Launch of GranuFlo Lawsuit Center
9. GranuFlo Recall Lawyers at Wright & Schulte LLC Investigating GranuFlo Lawsuits on Behalf of Dialysis Patients Allegedly Injured by GanuFlo or NaturaLyte
10. Granuflo Multidistrict Litigation Moves Forward: Now, AttorneyOne Can Provide Advice
11. GranuFlo Lawsuit News: W.Va. Man’s Lawsuit Goes to Federal Court, Rottenstein Law Group LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat , a smart ... and providing demos of its smart journaling platform at the 125th American Psychological ... D.C. from August 3-6, 2017. , The APA Annual Convention is one of ...
(Date:7/25/2017)... WI (PRWEB) , ... July 25, 2017 , ... ... Aloria Health, as medical director. Dr. Negrette has more than a decade of ... She has worked closely with individuals fighting addictions, eating disorders, psychotic and manic ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
(Date:7/24/2017)... ... 2017 , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been ... (SLMBNI), part of Saint Luke’s Health System . Dr. Upadhyaya has served in ... M.Sc., FAANS joins Stanley P. Fisher, M.D., who has served as medical ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services ... Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. ... will facilitate the development of a hub and spoke model for opioid treatment ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
Breaking Medicine Technology: